User:Mr. Ibrahem/Zafirlukast

Mr. Ibrahem/Zafirlukast
Clinical data
Trade names	Accolate, others
AHFS/Drugs.com	Monograph
MedlinePlus	a697007
Pregnancy; category	AU: B1; ;
Routes of; administration	By mouth
Drug class	Leukotriene receptor antagonist
Legal status
Legal status	UK: POM (Prescription only);
Pharmacokinetic data
Bioavailability	Unknown
Protein binding	>99% (albumin)
Metabolism	Liver (CYP2C9-mediated)
Metabolites	hydroxylated metabolites
Onset of action	< 2 weeks
Elimination half-life	10 hours
Excretion	Fecal
Identifiers
	IUPAC name Cyclopentyl 3-{2-methoxy-4-[(o-tolylsulfonyl)carbamoyl]benzyl}-1-methyl-1H-indol-5-ylcarbamate;
Chemical and physical data
Formula	C31H33N3O6S
Molar mass	575.68 g·mol−1
3D model (JSmol)	Interactive image;
Melting point	138 to 140 °C (280 to 284 °F)
	SMILES Cc1ccccc1S(=O)(=O)NC(=O)c2cc(OC)c(cc2)Cc3cn(C)c4ccc(cc43)NC(=O)OC5CCCC5;
	InChI InChI=1S/C31H33N3O6S/c1-20-8-4-7-11-29(20)41(37,38)33-30(35)22-13-12-21(28(17-22)39-3)16-23-19-34(2)27-15-14-24(18-26(23)27)32-31(36)40-25-9-5-6-10-25/h4,7-8,11-15,17-19,25H,5-6,9-10,16H2,1-3H3,(H,32,36)(H,33,35) ; Key:YEEZWCHGZNKEEK-UHFFFAOYSA-N ;
	(verify)

Zafirlukast, sold under the brand Accolate among others, is a medication used for the long term treatment of asthma and allergic rhinitis.^[1] It is less preferred to inhaled steroids for asthma.^[1] It is taken by mouth.^[1] Benefits may take up to two weeks to occur.^[1]

Common side effects include headache and stomach upset.^[1] Severe side effects may include liver problems and potentially Churg-Strauss syndrome.^[1] Use is likely safe in pregnancy.^[1] It is a leukotriene receptor antagonist (LTRA) and works by decreasing airway mucous, swelling, bronchoconstriction, and inflammation.^[1]

Zafirlukast was approved for medical use in the United States in 1996.^[1] It is approved in some but not all parts of Europe.^[3] In the United States it costs about 34 USD per month as of 2021.^[4]

References[edit]

^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ ^j ^k ^l ^m ⁿ "Zafirlukast". Archived from the original on 3 August 2020. Retrieved 4 August 2021.
^ ^a ^b ^c ^d "ACCOLATE (zafirlukast) Package Insert" (PDF). www.accessdata.fda.gov. AstraZeneca LP. Archived (PDF) from the original on 20 January 2017. Retrieved 29 November 2017.
^ "List of nationally authorised medicinal products Active substance: Zafirlukast" (PDF). Archived (PDF) from the original on 27 August 2021. Retrieved 4 August 2021.
^ "Zafirlukast Prices, Coupons & Savings Tips - GoodRx". GoodRx. Archived from the original on 31 January 2021. Retrieved 4 August 2021.

[AHFS2021-1] ^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ ^j ^k ^l ^m ⁿ "Zafirlukast". Archived from the original on 3 August 2020. Retrieved 4 August 2021.

[Accolate_PI-2] "ACCOLATE (zafirlukast) Package Insert" (PDF). www.accessdata.fda.gov. AstraZeneca LP. Archived (PDF) from the original on 20 January 2017. Retrieved 29 November 2017.

[3] "List of nationally authorised medicinal products Active substance: Zafirlukast" (PDF). Archived (PDF) from the original on 27 August 2021. Retrieved 4 August 2021.

[GX2021-4] "Zafirlukast Prices, Coupons & Savings Tips - GoodRx". GoodRx. Archived from the original on 31 January 2021. Retrieved 4 August 2021.

[1]

[2]

[3]

[4]